文献速递结核与非结核分枝杆菌病毒性肝炎

药物敏感结核HIRIF试验中肝毒性的药代动力学与药物基因组学预测因素

Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis.
PubMed 文献 · Clin Infect Dis · 2026-03-06

本研究基于HIRIF试验中接受利福平10、15或20 mg/kg/日治疗的药物敏感结核患者,分析肝毒性与利福平及其伴随药物药代动力学及NAT2基因型的关联。168例有药代动力学数据的参与者中,利福平剂量与暴露均与2级及以上ALT或AST升高无关;多变量分析仅吡嗪酰胺暴露与肝毒性相关,提示利福平暴露不增加肝毒性。

要点

  • 利福平剂量或暴露与2级及以上ALT/AST升高无关
  • 多变量分析中仅吡嗪酰胺暴露与肝毒性独立相关
  • NAT2慢乙酰化者肝毒性风险升高,但多变量分析后不独立

核心结论

  • 在HIRIF试验中,利福平暴露与肝毒性无关,多变量分析仅吡嗪酰胺暴露与2级及以上ALT或AST升高相关。

研究设计与样本

  • HIRIF试验参与者随机接受利福平10、15或20 mg/kg/日强化期治疗,采用Cox比例风险模型分析168例有药代动力学数据者的肝毒性危险因素。

主要发现

  • 单变量分析中,吡嗪酰胺暴露每增加50 mg*h/L AUC0-6h的HR为1.85,异烟肼暴露每增加5 mg*h/L AUC0-6h的HR为1.40,NAT2慢乙酰化相对快乙酰化HR为9.32(n=90),均与2级及以上ALT或AST升高相关。
  • 利福平剂量与暴露均与2级及以上ALT或AST升高无关。
  • 多变量分析中仅吡嗪酰胺暴露与肝毒性相关。

临床怎么用

  • 利福平暴露未显示与肝毒性相关,支持在更大规模试验中进一步评估最高20 mg/kg/日的剂量。
  • 接受含吡嗪酰胺方案者应关注吡嗪酰胺暴露与肝毒性风险。

局限性

  • NAT2基因型分析仅限90例子集,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatotoxicity is frequent in the standard-of-care regimen for drug-susceptible tuberculosis, yet the association of each companion drug with hepatotoxicity has not been fully characterized. We examined the association between hepatotoxicity and the pharmacokinetics of rifampin and its companion drugs in standard therapy, as well as N-acetyltransferase 2 (NAT2) genotype. METHODS: We evaluated HIRIF trial participants who were randomized to receive rifampin 10, 15, or 20 mg/kg/day during the intensive phase of tuberculosis treatment. We fitted Cox proportional hazards models to identify risk factors for grade 2 or higher (grade 2+) alanine transaminase (ALT) or aspartate transaminase (AST) elevation, and considered pharmacokinetic exposure of each antituberculosis drug and NAT2 genotype as potential covariates. RESULTS: Among 168 participants with pharmacokinetic data, neither rifampin dose nor exposure were associated with the risk of grade 2+ ALT or AST elevation. Higher pyrazinamide exposure (hazard ratio [HR] 1.85 for every 50 mg*h/L AUC0-6h increase), higher isoniazid exposure (HR 1.40 for every 5 mg*h/L AUC0-6h increase), and among a subset with known NAT2 genotype, slow NAT2 acetylator status (HR 9.32 relative to fast, n=90) were associated with grade 2+ ALT or AST elevation in univariable analysis. In multivariable analysis, only pyrazinamide exposure was associated with hepatotoxicity. CONCLUSIONS: While higher pyrazinamide and isoniazid exposures and slow NAT2 acetylator status were each associated with increased hepatotoxicity, only pyrazinamide exposure was associated when considering pharmacokinetic variables together. Rifampin exposure was not associated with hepatotoxicity, supporting further evaluation of doses up to 20 mg/kg/day in a larger trial.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Yang E, Van Brantegem P, Peloquin CA, et al. Pharmacokinetic and pharmacogenomic predictors of hepatotoxicity in the HIRIF trial for drug-susceptible tuberculosis. Clin Infect Dis. 2026. PMID: 41789820. doi:10.1093/cid/ciag141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。